Summary
The provided AI-generated claims are about cost/coverage and related programs, brand/biosimilar approval, pricing, and manufacturer/program details. The supplied FDA label excerpts concern serious infections and malignancies, and do not provide information needed to verify or refute these non-label claims. As a result, most statements are unsupported by the provided prescribing information.
Category Scores
Accurate Statements
Unsupported Statements
The cost of Enbrel injection can vary depending on dose, frequency of administration, and location where it's prescribed.
No cost, pricing, or variability information is provided in the supplied FDA label excerpts.
The typical cost of a one-month supply of Enbrel injection (a 20-mL vial or a 28-day supply of individual 0.5-mL vials) ranges from around $4,000 to $6,000.
No cost or pricing amounts are provided in the supplied FDA label excerpts.
With a copay card and insurance coverage, patients may pay as little as $5 to $20 per use.
No copay card, patient payment limits, or affordability figures are provided in the supplied FDA label excerpts.
In the United States, Enbrel is a brand-name medication.
The supplied FDA label excerpts do not discuss branding/brand vs generic status.
The cost of Enbrel is generally not covered by Medicare unless the patient has a specific condition covered under their plan.
No Medicare coverage policy information is provided in the supplied FDA label excerpts.
The cost of Enbrel is generally not covered by Medicaid unless the patient has a specific condition covered under their plan.
No Medicaid coverage policy information is provided in the supplied FDA label excerpts.
Some private insurance plans may cover Enbrel.
No private insurance coverage information is provided in the supplied FDA label excerpts.
Etanercept-SNZ is a biosimilar version of Enbrel.
The supplied FDA label excerpts do not discuss biosimilars or etanercept-SNZ.
Etanercept-SNZ was approved by the FDA in 2020.
No FDA approval timeline or approval year for etanercept-SNZ is provided in the supplied FDA label excerpts.
Etanercept-SNZ is expected to be significantly cheaper than brand-name Enbrel.
No comparative pricing expectations are provided in the supplied FDA label excerpts.
Prices for Etanercept-SNZ are stated to start at around $2,300 per month.
No biosimilar price information is provided in the supplied FDA label excerpts.
Biosimilars may not be universally available yet.
No availability/market distribution information is provided in the supplied FDA label excerpts.
Adoption of biosimilars depends on factors including individual insurance plans and regulatory approvals.
No biosimilar adoption or insurance/regulatory adoption factors are provided in the supplied FDA label excerpts.
AbbVie offers an Enbrel Patient Savings Program (patient assistance program).
No patient savings/assistance program or manufacturer program information is provided in the supplied FDA label excerpts.
The Enbrel Patient Savings Program provides eligible patients with a $5,000 rebate per month for up to 12 months.
No rebate amounts, eligibility, duration limits, or assistance program details are provided in the supplied FDA label excerpts.
The Enbrel Patient Savings Program rebate ends when patients are eligible for Medicare, whichever comes first.
No Medicare eligibility timing, rebate termination criteria, or assistance program rules are provided in the supplied FDA label excerpts.
AbbVie is the manufacturer of Enbrel.
No manufacturer information is provided in the supplied FDA label excerpts.
The source text refers to 'Enbel' as the manufacturer name associated with the patient assistance program.
No discussion of any manufacturer name spelling variants is provided in the supplied FDA label excerpts.
Contradictions
Important Omissions
No statements address label-supported risks (serious infections, including TB and opportunistic infections; malignancies including lymphoma/leukemia and skin cancer; and monitoring/discontinuation guidance).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The provided claims do not cite or alter the drug’s labeled safety warnings (serious infections/malignancies). However, because the claims are largely unsupported by the supplied prescribing information (which does not cover cost/coverage/program details), they could mislead users about logistics/affordability rather than directly about treatment risks.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are outside the scope of the provided FDA label excerpts and are therefore unsupported by the supplied prescribing information (primarily cost/coverage/program/biosimilar statements).
Suggested Improvement
Evaluate and restrict claims to information contained in the provided FDA label sections (e.g., serious infections and malignancies). Provide additional label excerpts (e.g., full prescribing information sections on indications, dosing, contraindications, and any sections mentioning manufacturer or patient assistance, if present) before making or scoring cost/coverage/program/manufacturer/biosimilar claims.